Alopecia Areata: Diagnostic and Therapeutic Recommendations of the Polish Society of Dermatology. Part 2: Treatment

The document outlines the treatment recommendations for alopecia areata by the Polish Society of Dermatology. The treatment goal is to induce hair regrowth and prevent disease progression, with the approach varying based on the disease's severity, measured by the SALT or AAS. For mild cases, high potency topical glucocorticoids and intralesional triamcinolone acetonide are recommended. Moderate to severe cases typically require systemic treatment, with baricitinib being the only drug currently approved in Europe and the US specifically for alopecia areata. Ritlecitinib is anticipated to be the next approved drug. Other systemic treatments include glucocorticoids, cyclosporine, and methotrexate, and contact immunotherapy is also an option. Long-term maintenance treatment is emphasized as important for managing alopecia areata.